AI assistant
CRISPR Therapeutics AG — Director's Dealing 2020
Aug 5, 2020
30936_dirs_2020-08-05_0b292f24-3ee3-4d1d-bf14-84ceff115cbe.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: CRISPR Therapeutics AG (CRSP)
CIK: 0001674416
Period of Report: 2020-08-03
Reporting Person: TOMSICEK MICHAEL JOHN (Chief Financial Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2020-08-03 | Common Shares | M | 12000 | $17.75 | Acquired | 12410 | Direct |
| 2020-08-03 | Common Shares | S | 6552 | $86.2528 | Disposed | 5858 | Direct |
| 2020-08-03 | Common Shares | S | 5448 | $87.333 | Disposed | 410 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2017-11-13 | Stock Option (Right to Buy) | $17.75 | M | 12000 | Disposed | 2027-11-21 | Common Shares (12000) | Direct |
Footnotes
F1: Includes 410 shares acquired under the CRISPR Therapeutics AG 2016 Employee Stock Purchase Plan.
F2: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.78 to $86.77, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $86.875 to $87.80, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
F5: This option was granted on November 13, 2017, 25% of the shares vested on November 13, 2018 and the remaining shares vest in 36 equal monthly installments on the first day of each succeeding calendar month.